You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Timeline
Mendeley readers
Chapter title |
Targeting HER2 in Advanced Breast Cancer
|
---|---|
Chapter number | 4 |
Book title |
ErbB Receptor Signaling
|
Published in |
Methods in molecular biology, January 2017
|
DOI | 10.1007/978-1-4939-7219-7_4 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7218-0, 978-1-4939-7219-7
|
Authors |
Xiaofu Zhu, Anil Abraham Joy |
Abstract |
Human epidermal growth factor receptor 2 (HER2) is a human oncogene that is amplified in approximately 20% of breast cancers, and portends a worse prognosis if not treated with anti-HER2 agents. The advent of targeted anti-HER2 therapies has dramatically improved disease control and survival in patients with metastatic HER2-positive breast cancer, and is now considered standard of care in the first-line setting and beyond. This review summarizes the currently available data on targeted anti-HER2 therapies from completed randomized phase III clinical trials, and briefly discusses emerging advances that will address unmet needs in metastatic HER2-positive breast cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 18% |
Student > Master | 6 | 16% |
Student > Bachelor | 4 | 11% |
Student > Ph. D. Student | 3 | 8% |
Other | 2 | 5% |
Other | 5 | 13% |
Unknown | 11 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 18% |
Medicine and Dentistry | 7 | 18% |
Economics, Econometrics and Finance | 4 | 11% |
Mathematics | 1 | 3% |
Nursing and Health Professions | 1 | 3% |
Other | 5 | 13% |
Unknown | 13 | 34% |